ClinicalTrials.gg
RecruitingNCT06908421SiASMARTerUpdated Sep 5, 2025

Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence

An observational study in Asthma, sponsored by Chiesi Pharma AB, Nordic. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Chiesi Pharma AB, Nordic (part of Chiesi Farmaceutici S.p.A.) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
14th of 15
60 · median 300
Started
2025
with 4 others
Observational
15 of 81
6 open now
Primary completion
2027-09
later than 6 of 10 live
Registered
75th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2025, is one of 15 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 75th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI inhalers. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments.

The main questions it aims to answer are:

  • Can the SiA® system improve inhaler use and medication adherence in asthma patients?
  • Does improving inhaler technique and adherence lead to better asthma control and reduced airway inflammation (measured by FeNO levels)?

Participants will:

  • Use the SiA® system, which includes a smart inhaler cap (RespiPRO™) and a mobile app
  • Continue their prescribed Trimbow pMDI treatment for asthma.
  • Have their asthma control, lung function, and FeNO levels monitored at specific points over 1 year (3 months and 12 months).

The study does not have a comparison group and all results will be compared to baseline.

Read the detailed description

Background and Rationale Asthma is a chronic inflammatory disease of the airways that affects millions of individuals worldwide. Despite the availability of effective inhaled medications, poor adherence and incorrect inhaler technique remain major barriers to optimal asthma control. Studies show that up to 86.7% of asthma patients make at least one inhaler technique error, and 30-40% demonstrate poor adherence to their prescribed medication. These factors contribute to worsened symptoms, increased healthcare utilization, and reduced quality of life.

The SiA® system, developed by Briota ApS, aims to address these challenges by integrating a smart inhaler cap (RespiPRO™) with a mobile application. This system provides real-time feedback on inhaler technique and adherence, allowing patients and healthcare providers to track progress and make necessary adjustments.

This study seeks to determine whether using the SiA® system alongside a pressurized metered dose inhaler (pMDI) therapy can lead to measurable improvements in medication adherence, inhalation technique, and asthma control. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by inadequate treatment caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of therapy. Potentially those who might become candidate for biological treatments.

Study Design This is a prospective, single-arm observational study conducted at two hospitals in Denmark. It is designed to assess how the SiA® System impacts inhaler technique and medication adherence over a 12-month period.

Key Features of the Study Design:

  • Observational (non-interventional): Participants will continue their standard asthma medication (Trimbow pMDI) but will use the SiA® system to monitor their inhaler technique and adherence.
  • Single-arm design: All participants will receive the SiA® System - there is no comparison group.
  • Real-world setting: The study aims to reflect how patients interact with the SiA® system in everyday life, outside of a controlled clinical trial environment.

Study Setting:

  • Conducted at two specialized respiratory clinics in Denmark.
  • Participants will be recruited from routine asthma care visits.

Data Collection Methods:

Data will be collected through multiple sources:

  • Hospital medical records (to gather historical asthma data and prior exacerbation history).
  • Spirometry tests (to assess lung function).
  • FeNO tests (to measure airway inflammation).
  • SiA® System data (to track inhaler adherence and technique).
  • Patient-reported outcome measures (questionnaires on asthma symptoms and quality of life).

Technology Used in the Study:

  • RespiPRO™ Smart Inhaler Cap: A device that attaches to Trimbow pMDI and records inhaler usage data.
  • SiA® Mobile App: Tracks daily inhaler use, provides feedback, and sends adherence reminders.

Study Timeline:

Total Study Duration: 22 months, with individual patient follow-up lasting 12 months (52 weeks).

Patient Flow and Study Visits:

  1. Screening and Baseline Visit (Week 0) - Study Enrolment

    • Patients will be identified during routine asthma care visits and screened for eligibility.
    • Informed consent will be obtained.
    • Baseline data collection will include:
    • Medical history
    • Asthma severity and medication use
    • Spirometry test (lung function)
    • FeNO test (airway inflammation)
    • ACT (Asthma Control Test) and mini-AQLQ (Asthma Quality of Life Questionnaire)
    • Patients will receive a brief training session on how to use the SiA® System.
    • A baseline inhaler technique video will be recorded using the SiA® Mobile App.
  2. Interim Follow-up Visit (Week 12) - Progress Check

    • Patients will return for an in-person visit.
    • Repeat measurements:

      • FeNO test (to check inflammation levels).
      • Spirometry (lung function test).
      • ACT and mini-AQLQ (patient-reported outcomes).
    • Adherence data from the SiA® system will be reviewed.
    • Patients will complete a satisfaction survey about their experience with the SiA® system.
  3. Final Study Visit (Week 52) - End of Study

    • Repeat FeNO, spirometry, ACT, and mini-AQLQ assessments.
    • The final inhaler technique video will be recorded and analyzed.
    • Patients will return or deactivate the RespiPRO™ Smart Inhaler Cap.
    • Final adherence and inhalation technique data will be collected from the SiA® Dashboard.

Potential Impact of the Study

This study aims to generate real-world evidence on how digital health interventions can improve asthma management. If successful, the SiA® System could:

  • Enhance asthma control by ensuring patients use their inhalers correctly.
  • Reduce unnecessary medication escalation, preventing overuse of corticosteroids.
  • Lower healthcare costs by reducing asthma-related hospital visits.
  • Empower patients with real-time feedback and better self-management tools.
  • Improve and optimize the way asthma patients become candidate for biological treatments
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Inhaler treatment
  • smart add-on device
  • adherence
  • inhaler technique
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Asthma patients above 18 years of age, with objectively verified diagnosis of asthma according to GINA, uncontrolled T2 inflammation (FeNO >25ppm) on BDP/FF/G inhalation treatment with prescribed rescue medication (SABA).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age.
  2. Objectively verified leading diagnosis of asthma according to GINA
  3. FeNO >25 ppb.
  4. Treated with Trimbow 87/5/9 pMDI for >4 weeks before enrolment,

    1. with prescribed rescue medication (SABA).
    2. with and without prescription of a spacer.
  5. Being literate Danish.
  6. Having a personal Android/iOS phone and 4G/5G internet connection.
  7. Comfortable using a smart phone and Bluetooth enabled Digital Devices.
  8. Willingness to participate in the study, understand the written patient information and being able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Participation in a clinical trial within 4 weeks prior to enrolment into the present study or planned enrolment in a clinical trial during the observational period.
  2. Use of systemic as maintenance treatment.
  3. Treated with biologics (that is monoclonal antibodies).
  4. Concomitant diagnosis of .
  5. Lung cancer or history of lung cancer.
  6. Respiratory tract infection/exacerbation within 4 weeks prior to enrolment.
  7. Use of oral corticosteroids within 4 weeks before enrolment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study population

    Asthma patients above 18 years of age, with objectively verified diagnosis of asthma according to GINA, uncontrolled T2 inflammation (FeNO \>25ppm) on BDP/FF/G inhalation treatment with prescribed rescue medication (SABA).

06

What researchers measure

Primary outcomes

  1. To evaluate the impact of the SiA® platform on the level of the type 2 inflammation biomarker FeNO

    To assess the impact of the study on the type 2 biomarker FeNO with a change from baseline of at least 20% will be considered clinically relevant. FeNO values will be presented as ppb. FeNO levels of \< 25 ppb, 25 - 50 ppb, \> 50 ppb, are considered low, medium, and high respectively.

    Time frame: Change from baseline in FeNO at week 12 and 52.

Secondary outcomes

  1. To assess the impact of the SiA® platform on adherence to SITT and inhaler technique measure using the RespiPRO add-on module

    Change in inhaler adherence measured as percentage of days covered and inhaler technique scores based an assessments of inhalation video recordings an data collected from the SiA® platform using a scoring system of 1-5, where 5 = Optimal technique; 4 = Poor technique with one critical error; 3 = Poor technique with two critical errors; ≤2 = Poor technique with three or more critical errors. The RespiPRO™ cannot monitor step 1 and 2, thus are these by default set to 1, hence the minimum inhaler technique scores achievable from RespiPRO™ is 2.

    Time frame: Change in pMDI inhaler technique score and medication adherence score at week 12 and 52 compared to baseline.

  2. To evaluate the impact of the SiA® platform on asthma control using Asthma Control Test

    Asthma control will be assesed using Asthma Control Test (ACT), which is a patient self-administred tool for identifying those with poorly controlled asthma. A maximum score of 25 points indicates complete asthma control. A score between 20 and 25 represents well controlled asthma, while a score of 19 or below represents not well controlled asthma, and a score less than 16 indicates very poorly controlled asthma.

    Time frame: Change in ACT scores from baseline at weeks 12 and 52

  3. To evaluate the impact of the SiA® platform on health-related quality of life

    To assess the impact of the study on Health-related Quality of Life (HR QoL) using Asthma Quality of Life Questionnaire (mini-AQLQ). The mini-AQLQ has 15 questions in the same domains as the original AQLQ (symptoms, activities, emotions and environment).

    Time frame: Change in mini-AQLQ scores from baseline at weeks 12 and 52

  4. To evaluate the impact of the SiA® platform on lung function measured by spirometry

    Change in lung function parameters (change in mean FEV1, FEV1 %-predicted, FEV1/FVC ratio, FEF25-75) from baseline at weeks 12 and 52

    Time frame: From baseline and at week 12 and 52.

  5. To evaluate the impact of the SiA® platform on shifts in FeNO category

    Change in FeNO category (low, intermediate, high) defined as (\< 25 ppb, 25 - 50 ppb, \> 50 ppb, respectively.

    Time frame: Change from baseline at week 12 and 52.

  6. To evaluate the impact of the SiA® platform on annualized exacerbations rates

    Retrospective data from the past 12 months will gathered the number of moderate and severe exacerbations as defined by the American Thoracic Society/European Respiratory Society.

    Time frame: Change in annualized exacerbation rates (moderate and severe) from baseline at week 52

  7. o evaluate the impact of the SiA® platform on the use of rescue medication (SABA)

    To assess the impact of the study intervention on use of rescue medication (SABA) measured as average puffs per day/week/month.

    Time frame: Change from baseline (first 7 days after entering the study) in the use of rescue medication (SABA) at week 12 and 52).

  8. Satisfaction and compliance with add-on device based on a customized survey

    Satisfaction score at week 52 assessed using a customized questionnaire. The survey reports on 9 question related to the satisfaction with SiA® platform. Each of the 9 question can be given a score from 1-5. where 1 = very difficult/dissatisfied, 3 = neutral, and 5 = very easy/satisfied.

    Time frame: at week 52.

07

Study locations

2 of 2 sites recruiting
  • Copenhagen University Hospital-Hvidovre
    Hvidovre, Capital Region DK-2650, Denmark
    Recruiting
    • Charlotte S Ulrik, MD, DMSc, FERS · Contactcharlotte.Suppli.Ulrik@regionh.dk · +4538622177
    • Charlotte S Ulrik, charlotte.Suppli.Ulrik@regionh · Principal investigator
  • Aarhus University Hospital
    Aarhus, Central Jutland DK-8200 Aarhus N, Denmark
    Recruiting
    • Johannes M Schmid, PhD, ass. professor · Contactjoschm@rm.dk · +4578462106
    • Johannes M Schmid, PhD, ass. professor · Principal investigator
08

References and documents

Publications

  • Baekdal JA, Krogh N, Sakhare G, Bendstrup E, Ulrik CS, Schmid JM. Study protocol: a 52-week, multicentre, observational, prospective study on the use of a smart platform connected to a single-inhaler triple therapy (ICS/LABA/LAMA) to evaluate effectiveness on treatment adherence and inhaler technique in patients with poorly controlled asthma. BMC Pulm Med. 2026 Jul 7. doi: 10.1186/s12890-026-04454-1. Online ahead of print. PubMed 42414967 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 24 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 3, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06908421
Collaborators
Briota ApS
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 5, 2025

Study contacts

Nicolai Krogh, PhD
Contact
n.krogh@chiesi.com
+4526850170
Johannes M Schmid, PhD, ass. professor
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion